Codonopsis lanceolata is a perennial smelly herbaceous plant and widely employed for the
treatment of various lung cancer and inflammation. However, the anticancer substances in …

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic driver
in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase …

Homeostasis is achieved by balancing cell survival and death. In cancer cells, especially
those carrying driver mutations, the processes and signals that promote apoptosis are …

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrotic disease. Recent studies
have highlighted the persistence of an intermediate state of alveolar stem cells in IPF lungs …

Background Tyrosine kinase and phosphoinositide kinase pathways play important roles in
asthma formation. As a dual tyrosine and phosphoinositide kinase inhibitor, PP121 has …

Triple-negative breast cancer (TNBC) is a severe threat to women's health because of its
aggressive nature, early age of onset, and high recurrence rate. Therefore, in this study, we …

Diarrhea is an important adverse effect of epidermal growth factor receptor-tyrosine kinase
inhibitors, especially afatinib. Novel antidiarrheal agents are needed to reduce epidermal …

The targeted agents capmatinib and tepotinib provide a new treatment for patients with non-
small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). However …

Secondary pharmacology screening of investigational small-molecule drugs for potentially
adverse off-target activities has become standard practice in pharmaceutical research and …

Transformation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is
rare and is associated with poor prognosis. However, the standard treatment protocols for …